Phase I-Ib Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin as First-line Therapy in Patients With Advanced or Metastatic Cancer Suitable for a Carboplatin and Pemetrexed Regimen as Part of Their Specific Therapy
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2017
At a glance
- Drugs Tivantinib (Primary) ; Carboplatin; Pemetrexed
- Indications Mesothelioma; Non-small cell lung cancer
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 09 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 20 Jul 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2016.